These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17962902)

  • 1. Prolonged persistence of lamivudine-resistant mutant and emergence of new lamivudine-resistant mutants two years after lamivudine withdrawal in HBsAg-positive chronic hepatitis patient: a case report.
    Orlando R; Tosone G; Portella G; Veropalumbo E; D'Onofrio M; Piazza M
    Infection; 2008 Oct; 36(5):472-4. PubMed ID: 17962902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and virological effects of long-term (over 5 years) lamivudine therapy.
    Hashimoto Y; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saito S; Suzuki Y; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2010 Apr; 82(4):684-91. PubMed ID: 20166170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy.
    Yeh CT; Chien RN; Chu CM; Liaw YF
    Hepatology; 2000 Jun; 31(6):1318-26. PubMed ID: 10827158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
    Natsuizaka M; Hige S; Ono Y; Ogawa K; Nakanishi M; Chuma M; Yoshida S; Asaka M
    J Viral Hepat; 2005 Mar; 12(2):154-9. PubMed ID: 15720530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
    Liaw YF
    Antivir Chem Chemother; 2001; 12 Suppl 1():67-71. PubMed ID: 11594691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B.
    Tsubota A; Arase Y; Suzuki F; Kobayashi M; Matsuda M; Sato J; Suzuki Y; Akuta N; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Med Virol; 2004 May; 73(1):7-12. PubMed ID: 15042641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine.
    Matsuda M; Suzuki F; Suzuki Y; Tsubota A; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Satoh J; Takagi K; Kobayashi M; Ikeda K; Kumada H
    J Gastroenterol; 2004 Jan; 39(1):34-40. PubMed ID: 14767732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy.
    Liaw YF; Chien RN; Yeh CT; Tsai SL; Chu CM
    Hepatology; 1999 Aug; 30(2):567-72. PubMed ID: 10421670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy.
    Gwak GY; Huh W; Lee DH; Choi MS; Lee JH; Koh KC; Kim SJ; Joh JW; Oh HY
    Transplant Proc; 2007 Dec; 39(10):3121-6. PubMed ID: 18089336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis.
    Chan HL; Chui AK; Lau WY; Chan FK; Hui AY; Rao AR; Wong J; Lai EC; Sung JJ
    Clin Transplant; 2004 Jun; 18(3):295-300. PubMed ID: 15142051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected during lamivudine therapy.
    Lee SH; Kim HS; Byun IS; Jeong SW; Kim SG; Jang JY; Kim YS; Kim BS
    J Med Virol; 2012 Feb; 84(2):217-22. PubMed ID: 22170540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy.
    Yen YH; Lu SN; Chen CH; Wang JH; Wu CM; Hung CH; Tseng PL; Hu TH; Changchien CS; Lee CM
    Liver Int; 2007 Dec; 27(10):1349-55. PubMed ID: 18036099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Types and emergence time of YMDD motif mutation in hepatitis B virus polymerase gene during lamivudine treatment].
    Liang WF; Yang DH; Shen YH; Xie YJ; Zhao NF
    Zhonghua Gan Zang Bing Za Zhi; 2003 May; 11(5):302-4. PubMed ID: 12773248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus quantification and detection of YMDD mutants in a single reaction by real-time PCR and annealing curve analysis.
    Shih YH; Yeh SH; Chen PJ; Chou WP; Wang HY; Liu CJ; Lu SF; Chen DS
    Antivir Ther; 2008; 13(4):469-80. PubMed ID: 18672526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy.
    Kim JW; Lee HS; Woo GH; Yoon JH; Jang JJ; Chi JG; Kim CY
    Clin Infect Dis; 2001 Aug; 33(3):403-5. PubMed ID: 11438912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains.
    Hosseini SY; Sabahi F; Amini-Bavil-Olyaee S; Alavian SM; Merat S
    J Virol Methods; 2006 Nov; 137(2):298-303. PubMed ID: 16962669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative subtyping of hepatitis B virus reveals complex dynamics of YMDD motif mutants development during long-term lamivudine therapy.
    Ding C; Wong VW; Chow KC; Chan HY; Hui AY; Wong GL; Lo YM; Sung JJ; Chan HL
    Antivir Ther; 2006; 11(8):1041-9. PubMed ID: 17302374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.